Sudarshan Pharma Industries

₹33.33As of Sun 8 Nov 2026, 12:00 UTC

NSE:SUDARSHAN—

Country India

PE (Fwd) 27.12

TSR 10Y CAGR —

Div yield —

ROE —

Pharmaceutical Preparations

Beta (5Y) 0.88

PE TTM 34.83

TSR TTM —

Mkt cap ₹8.525B

ROIC —

SE Grade™

—

Value

—

Quality

Moat

—

1Y Price

Reference

₹36

—

9.23%

—

TTM

FYE 31 Mar INR

FY2017

FY2018

FY2019

FY2020

FY2021

FY2022

FY2023

FY2024

FY2025

FY2026

FY2027E

Trend

10Y

Peers

7.031

Revenue₹B

—

3.571

4.613

4.635

5.050

7.031

8.029

18.45%

39.21

Revenue growth%

—

29.19

0.48

8.95

39.21

14.20

19.07

—

11.87

Gross margin%

—

6.08

6.58

8.84

12.91

11.87

11.89

8.84

6.90

Operating margin%

—

2.84

3.10

4.84

7.40

6.90

4.84

3.31

Net margin%

—

1.47

1.53

2.47

2.96

3.31

3.32

2.47

34.83

P/E ratio (avg)x

—

30.48

—

16.74

EV/EBITx

—

14.64

—

FCF yield (avg)%

—

FCF margin%

—

FCF / Net incomex

—

ROIC%

—

Return on equity%

—

Return on assets%

—

0.96

EPS₹

—

0.36

0.29

0.48

0.62

0.96

1.09

27.34%

—

55.17

EPS growth%

—

(19.65)

64.16

28.47

55.17

14.26

41.82

—

Bookvalue per sh₹

—

FCF per share₹

—

Dividend per sh₹

—

0.03

—

Div yield (avg)%

—

Payout ratio%

—

10.26

—

243.5

Shares (diluted)M

—

144.2

240.7

238.7

242.1

243.5

◌243.5

14.00%

(0.59)

Buyback yield%

—

(66.88)

0.83

(1.45)

(0.59)

◌—

(1.02)

—

D/E ratiox

—

8.117

Enterprise value₹B

—

8.117

—

LT debt₹M

—

Peers (US$86.44M)

Cap (US$)

Fermenta Biotech…

136.5M

25.81x

Bharat Parenterals…

136.0M

1,303x

Trident Lifeline…

52.57M

21.04x

October Pharma S.A.E

83.40M

27.22x

Capital

TTM

10Y

Leveragex

—

EBIT/Intx

2.121

2.852

Own earn%

—

Sh yield%

(0.59)

(1.02)

Owners

Insiders/Inst%

54.27

14.86

Short interest%

—

SBC / revenue%

—

Record

10Y

Profitable years

5/5

Revenue growth years

4/4

EPS growth years

3/4

Dividend streakyrs

Op margin range%

3–7

$1 testx

—

Incr. ROIC%

—

Sudarshan Pharma Industries Limited manufactures and sells specialty chemicals and intermediates for pharma, paints, food, adhesives, and various other industries in India and United States. The company also focuses on manufactures active pharmaceuticals ingredients and vitamins manufacturing.

Growth vs revenue

Latest

Trend

4Y CAGR

Rel growth

Revenue

₹7.031B

18.45%

1.00×

Cost of revenue

₹6.196B

16.58%

0.94×

Operating expenses

₹350.0M

31.92%

1.54×

Revenue by region

No breakdown available

Reinvestment returns

n/m

Trend

Reinvestment rate

n/m

Return on capital

n/m

Spread over hurdle

n/m